country house residences

What country house residences does

Country House Residences operates an in vitro diagnostics business (through the Tianjin-registered entity 完美体育·完美官方网站-完美体育(中国)) focused on quantitative immunoassay products for clinical use. Founded in January 2018 with 100 million RMB registered capital and headquartered at the Tianjin Beichen Economic and Technological Development Zone Biomedical Industrial Park, the company runs two core technology platforms: a fluorescent microsphere dry quantitative POCT system and a fully automated magnetic particle chemiluminescence immunoassay platform. Its 30+ commercialized reagents cover tumor markers, thyroid function, liver fibrosis (notably CHI3L1), bone metabolism (25-OH-D, PTH, N-MID Osteocalcin, P1NP, β-CTx), cardiac biomarkers (cTnI, CK-MB, MYO, NT-proBNP, D-Dimer, H-FABP), kidney markers (NGAL, Cys-C, MAU, RBP), inflammation (CRP, PCT, SAA), reproductive hormones (AMH, INHB), hepatitis B, and gastric disease (PG I/II, G-17). Proprietary features are protected by 17 patents spanning core chemistries, microfluidic chips, and three generations of fluorescent immunochromatographic analyzers.

Name

country house residences

Legal name

完美体育·完美官方网站-完美体育(中国)

Website

https://chresidences.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Country House Residences (operating entity: 完美体育·完美官方网站-完美体育(中国)) is a Chinese in vitro diagnostics manufacturer developing POCT and chemiluminescence immunoassay reagents and instruments for hospitals, examination centers, and third-party laboratories across China.

Ownership category

akta.pro rank

Product category

In Vitro Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

IVD Reagents, Assay Kits & Consumables (Non-instrument) (HLAHAAAM)

akta.pro secondary industry

Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes) (HLAGAIAI)

Keywords

• In vitro diagnostics
• POCT testing
• Chemiluminescence immunoassay
• Diagnostic reagent kits
• Clinical diagnostics

Headquarters

HQ city

Tianjin

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. 体外诊断试剂及仪器销售: The company generates revenue through the sale of in vitro diagnostic reagent kits and instruments. Products include POCT series (fluorescent immunochromatography) and chemiluminescence series. The company has over 30 industrialized products on the market.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

The company develops, manufactures, and sells in vitro diagnostic (IVD) reagent kits and analytical instruments based on two proprietary platforms: a fluorescent microsphere dry quantitative POCT detection system and a fully automated magnetic particle chemiluminescence immunoassay system. Its product line spans 30+ industrialized diagnostic reagents covering cardiac, kidney, inflammation, bone metabolism, thyroid, tumor, hepatitis, gastric, reproductive hormone, and women's and children's health panels, along with Savant-series POCT instruments. Products are sold to hospitals, examination centers, and third-party medical laboratories across China.

Product overview

完美体育·完美官方网站-完美体育(中国) is a high-tech enterprise specializing in in vitro diagnostics, offering two core technology platforms: fluorescent microsphere dry quantitative POCT system and fully automated magnetic particle chemiluminescence immunoassay system. The product portfolio includes diagnostic reagents across multiple categories including tumor markers, thyroid function, bone metabolism, cardiac biomarkers, kidney markers, inflammation markers, maternal and child health, gastric disease, reproductive hormones, and hepatitis B. The company provides both instruments (Savant series POCT devices and automated chemiluminescence analyzers) and配套试剂盒 (matching reagent kits) for clinical diagnostics in hospitals,体检中心, and medical laboratories.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• COVID-19 antigen test shows 89.80% total compliance with nucleic acid testing results

Named customers6 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Autobio Diagnostics: Major Chinese IVD company with a strong chemiluminescence (AutoLumo) and microbiology portfolio, sold into the same tertiary and county-level hospitals as the subject company; same reagent-menu strategy across tumor, thyroid, infectious disease and hormones.
• Guangzhou Wondfo Biotech: China's leading POCT diagnostic company with strong presence in infectious disease / rapid testing including COVID-19 antigen kits — directly comparable POCT technology and self-testing / hospital channel overlap with the subject company's Savant and COVID antigen line.
• Snibe Diagnostic (Shenzhen New Industries Biomedical Engineering): Leading Chinese chemiluminescence immunoassay (CLIA) IVD manufacturer (MAGLUMI series), competing head-to-head with this company's chemiluminescence reagents in tumor markers, thyroid, hormones, and infectious disease — almost identical menu and channel into mid-tier Chinese hospitals.
• Beijing Hotgen Biotech: Chinese POCT and chemiluminescence IVD company with comparable menu (cardiac markers, infectious disease, tumor markers) and similar mid-tier hospital go-to-market motion; materially overlapping technology and customer profile.
• Maccura Biotechnology: Chinese IVD manufacturer with both chemiluminescence immunoassay and rapid (POCT) diagnostic platforms, directly comparable technology-stack breadth and reagent menu, sold into the same hospital-laboratory end market in China.

Others

• KingMed Diagnostics: Largest Chinese third-party medical testing laboratory chain — relevant because the subject company explicitly lists "third-party medical testing laboratories" as a customer segment; buying-customer relationship rather than direct competitor.

Emerging players

• Hangzhou Puwang Biotech (普望生物): Hangzhou-based specialty biomarker diagnostics company focused on liver fibrosis (CHI3L1 /壳多糖酶3样蛋白1) and other specialty markers — a niche emerging player currently in an active patent infringement dispute with the subject company over CHI3L1 reagents.

Broad incumbents

• Abbott Diagnostics (China): Global IVD major (ARCHITECT chemiluminescence, i-STAT POCT) directly overlapping the subject's reagent menu and target hospital channels in China; multinational pricing and brand compete against the subject's domestic-positioning advantage.
• Shenzhen Mindray Bio-Medical Electronics (Mindray): China's largest medical device / IVD company with a full chemiluminescence immunoassay platform (CL series) and broad installed base in Chinese hospitals. Directly comparable product (chemiluminescence + IVD reagents) and customer base but operates at materially larger scale across multiple device categories.
• Roche Diagnostics (China): Global IVD leader in chemiluminescence (cobas) and POCT; competes at the high end of the same Chinese hospital accounts that the subject company targets, with substantially broader menu, larger trials footprint, and established KOL relationships.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/country-house-residences

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about country house residences